Preclinical & Discovery Programs

In addition to RA101495 and the Ra Pharma® collaboration with Merck, the Company has discovery and preclinical programs targeting selective inhibition of other complement factors, including Factor D administered by intravitreal injection for Dry Age-Related Macular Degeneration (AMD), Factor D administered SC for C3 Glomerulonephritis (C3GN) and Dense Deposit Disease (DDD), an oral, small molecule C5 inhibitor and C1s inhibitors for certain autoimmune and CNS diseases.